List of Excipients in Branded Drug VERKAZIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Santen Incorporated	VERKAZIA	cyclosporine	65086-001	CETALKONIUM CHLORIDE
Santen Incorporated	VERKAZIA	cyclosporine	65086-001	GLYCERIN
Santen Incorporated	VERKAZIA	cyclosporine	65086-001	MEDIUM-CHAIN TRIGLYCERIDES
Santen Incorporated	VERKAZIA	cyclosporine	65086-001	POLOXAMER 188
Santen Incorporated	VERKAZIA	cyclosporine	65086-001	SODIUM HYDROXIDE
Santen Incorporated	VERKAZIA	cyclosporine	65086-001	TYLOXAPOL

Verkazia Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Verkazia is a preservative-free, single-dose ophthalmic emulsion containing cyclosporine 0.1% for vernal keratoconjunctivitis, or VKC, in patients aged 4 years and older. Its commercial differentiation depends on delivery technology as much as on cyclosporine. The formulation uses a lipid-emulsion system with cetalkonium chloride, glycerol, medium-chain triglycerides, poloxamer 188, tyloxapol, sodium hydroxide, and water for injection. The main opportunity is to improve ocular residence time, tolerability, manufacturing efficiency, and device compatibility without compromising the emulsion’s particle-size and stability profile.[1]

What excipients are used in Verkazia?

The FDA prescribing information identifies the following inactive ingredients:

Excipient	Likely formulation role
Cetalkonium chloride	Cationic surfactant; contributes to emulsion stabilization and ocular surface interaction
Medium-chain triglycerides	Oil phase; solubilizes or carries cyclosporine
Tyloxapol	Nonionic surfactant; supports wetting and emulsion stabilization
Poloxamer 188	Nonionic surfactant and steric stabilizer
Glycerol	Tonicity and viscosity adjustment
Sodium hydroxide	pH adjustment
Water for injection	Continuous aqueous phase

Verkazia is supplied in preservative-free, single-dose containers. The product must be shaken before use because the formulation is an emulsion rather than a clear solution.[1]

The excipient strategy addresses four technical problems: cyclosporine’s very low aqueous solubility, delivery to the corneal surface, physical stability during storage, and pediatric tolerability. Cetalkonium chloride is particularly important because it gives the emulsion a cationic character that can increase interaction with the negatively charged ocular surface. That same feature creates a tolerability and concentration-control requirement.

How does Verkazia’s excipient system work?

Verkazia uses an oil-in-water emulsion to deliver cyclosporine to the ocular surface. Medium-chain triglycerides provide the dispersed oil phase. Surfactants reduce interfacial tension and help maintain the droplet population during manufacture and storage.

The excipient system has three commercial consequences:

1. Cyclosporine can be administered at 0.1% without relying on a fully aqueous solution.
2. The formulation can remain preservative-free, which is relevant for chronic pediatric use.
3. The product requires controlled shaking and single-dose packaging, creating higher packaging cost than a conventional multidose solution.

The formulation is closer to a drug-delivery platform than to a simple inactive-ingredient vehicle. Small changes in surfactant grade, oil composition, pH, droplet size, zeta potential, viscosity, or container material can affect performance. A follow-on product therefore faces a more complex equivalence program than a conventional aqueous ophthalmic generic.

What commercial opportunities exist around Verkazia excipients?

The largest opportunities are in excipient supply, formulation development, packaging, and contract manufacturing.

Specialty ophthalmic excipient supply

Suppliers with validated pharmaceutical grades of medium-chain triglycerides, cetalkonium chloride, tyloxapol, and poloxamer 188 can target ophthalmic manufacturers seeking dual sourcing. The relevant value proposition is not simple commodity supply. It is control over:

• Endotoxin and bioburden
• Peroxide and oxidation levels
• Trace metals
• Surfactant impurity profiles
• Lot-to-lot particle-size impact
• Compatibility with sterilization and aseptic processing

Ophthalmic manufacturers generally require tighter control than oral products because small changes in impurities or osmolality can produce local irritation.

Cationic emulsion platforms

A developer that owns a robust cationic ophthalmic-emulsion platform could pursue several indications beyond VKC. Potential targets include dry eye disease, keratitis, postoperative inflammation, allergic conjunctivitis, and other anterior-segment disorders requiring prolonged surface exposure.

The commercial advantage is formulation reuse. A platform can support multiple active ingredients, but each product requires separate clinical and CMC validation. The strongest opportunity is a platform that can maintain preservative-free delivery while reducing dosing frequency or improving comfort.

Improved preservative-free packaging

Verkazia’s single-dose format protects the formulation from repeated microbial contamination. Packaging suppliers can compete through:

• Lower-residual-volume ampoules
• Easier opening for pediatric caregivers
• Reduced plastic usage
• Better dose uniformity
• Improved shake-to-dose consistency
• Unit-dose systems compatible with automated filling

A multidose, preservative-free alternative would have substantial commercial value, but it would need a reliable sterile barrier and a validated microbial-control strategy. That approach could reduce packaging waste and improve adherence, although it would introduce a more demanding container-closure and in-use stability package.

Excipient substitution and supply-chain resilience

The formulation has several potential supply-chain pressure points. Cetalkonium chloride and tyloxapol are specialized ingredients relative to common ophthalmic excipients. A second-source strategy could reduce manufacturing risk for Santen or a competitor.

The most realistic substitution candidates are:

• Alternative nonionic surfactants
• Alternative medium-chain triglyceride grades
• Modified lipid mixtures
• Different polymeric stabilizers
• Alternative tonicity agents

Substitution is commercially attractive only if the replacement maintains the same critical quality attributes. A supplier that offers a technically equivalent excipient with a strong regulatory package could gain business even without changing the drug product’s clinical positioning.

What formulations are protected by Verkazia’s intellectual property?

Verkazia’s commercial protection is likely concentrated in formulation, manufacturing, and use patents rather than in the cyclosporine molecule itself. Cyclosporine is an old active ingredient, and broad composition-of-matter protection is unavailable.

Relevant protection categories include:

Protection category	Commercial relevance
Cationic ophthalmic emulsion	May cover the relationship between cyclosporine, oil phase, surfactant system, and charge
Specific excipient combinations	May limit substitution with closely related surfactants or oils
Particle size and physical stability	Can create manufacturing and equivalence barriers
Preservative-free unit-dose delivery	May protect packaging or dosing configurations
VKC treatment method	May protect use in pediatric vernal keratoconjunctivitis
Manufacturing process	May cover homogenization, sterilization, filling, or emulsion preparation

The key business distinction is between patent validity and practical design-around difficulty. A narrow patent directed to one excipient combination may be vulnerable to substitution. A patent covering a broad cationic emulsion architecture, supported by stability and clinical data, creates a stronger barrier.

What is the Orange Book status of Verkazia?

Verkazia was approved by the FDA in 2021 under NDA 214154 for VKC in patients aged 4 years and older.[1] The FDA Orange Book is the controlling source for current patent listings, expiration dates, pediatric exclusivity, and any regulatory exclusivity associated with the NDA.[2]

A generic applicant would normally assess:

• Listed patents covering the formulation
• Listed method-of-use patents for VKC
• Remaining five-year new-drug exclusivity, if applicable
• Pediatric exclusivity
• Paragraph IV exposure
• Whether the proposed labeling would require a section VIII statement or a carve-out

The active ingredient does not create the principal barrier. The commercial risk is concentrated in formulation patents, use patents, and the difficulty of demonstrating pharmaceutical equivalence for a complex emulsion.

When does Verkazia lose exclusivity?

The FDA approval date establishes the baseline for regulatory exclusivity, but market entry depends on the complete Orange Book record and litigation outcomes. FDA approval alone does not establish a single reliable generic-entry date.

For a potential generic, the relevant timeline is:

Event	Impact
FDA approval in 2021	Starts the product’s regulatory lifecycle
NDA patent listings	Define potential Paragraph IV exposure
Patent expiration	Removes the relevant statutory barrier
ANDA filing	Can trigger notice and litigation
Paragraph IV litigation	May create a 30-month stay if statutory requirements are met
Pediatric exclusivity	Can extend listed patent protection by six months
Approval of competing product	Does not necessarily permit immediate commercial launch

A business forecast should model at least three scenarios: no challenge before key patent expiry, an early Paragraph IV challenge followed by settlement, and litigation ending in invalidity or noninfringement. The formulation’s complexity makes an at-risk launch less attractive than it would be for a simple ophthalmic solution.

Which companies compete with Verkazia?

Verkazia competes across two dimensions: cyclosporine delivery and VKC treatment.

Product	Active ingredient	Dosage form	Main positioning
Verkazia	Cyclosporine 0.1%	Preservative-free emulsion	Pediatric VKC
Ikervis	Cyclosporine 0.1%	Emulsion	Severe keratitis associated with dry eye in Europe
Restasis	Cyclosporine 0.05%	Emulsion	Chronic dry eye disease
Cequa	Cyclosporine 0.09%	Nanomicellar solution	Chronic dry eye disease
Vevye	Cyclosporine 0.1%	Solution	Dry eye disease

Ikervis is the closest European formulation comparator because it also uses cyclosporine 0.1% in an ophthalmic emulsion. Restasis, Cequa, and Vevye compete for ophthalmologists’ familiarity with topical cyclosporine but target different primary indications.[3][4][5]

For VKC, the main competitive alternatives also include antihistamine/mast-cell stabilizer drops, topical corticosteroids, tacrolimus, and other immunomodulatory therapies. Steroids can provide rapid control but carry longer-term ocular risks. This supports Verkazia’s positioning as a steroid-sparing option for recurrent pediatric disease.

How strong is the Verkazia patent estate?

The estate is commercially meaningful but technically vulnerable to design-around.

Strength factors include:

• The formulation solves a difficult solubility problem.
• The product is preservative-free and intended for pediatric use.
• A cationic emulsion can create a differentiated delivery profile.
• Cyclosporine emulsion manufacturing requires specialized process control.
• A generic must address both formulation equivalence and ophthalmic product quality.

Weakness factors include:

• Cyclosporine is an established active ingredient.
• Many excipients are individually known.
• A competitor may substitute the oil phase or surfactant system.
• A solution, nanomicellar system, or different emulsion could avoid narrow claims.
• Method-of-use claims may be narrower than formulation claims.

The strongest enforceable position would combine broad formulation claims with validated performance data, including droplet size, surface charge, cyclosporine distribution, release, stability, and clinical tolerability.

What generic entry risks exist for Verkazia?

Generic entry risk is moderate rather than automatic. The principal barrier is not clinical development but pharmaceutical equivalence for a complex emulsion.

A generic applicant must manage:

• Same active ingredient concentration
• Comparable dosage form
• Equivalent or sufficiently justified inactive ingredients
• Emulsion droplet-size distribution
• Viscosity and osmolality
• pH
• Microbial quality
• Container-closure integrity
• Dose uniformity
• Stability after shaking
• Bioequivalence or other FDA-accepted equivalence evidence

An ANDA applicant may pursue a formulation that uses different excipients, but that choice can complicate equivalence and raise patent-infringement questions. A 505(b)(2) pathway could support a materially different formulation, but it would carry greater clinical and regulatory cost.

What licensing deals and manufacturing opportunities are available?

The most attractive licensing targets are delivery technologies that improve Verkazia’s limitations without changing the therapeutic concept. These include:

• Preservative-free multidose delivery
• Lower-frequency dosing
• Improved pediatric administration
• Reduced ocular stinging
• Longer ocular residence time
• Lower-cost emulsion manufacture
• Alternative sterilization or aseptic-fill processes
• Ready-to-use products that reduce shake-related variability

Santen owns and commercializes Verkazia in major markets, while European commercialization has involved regional regulatory and commercial structures associated with the product’s ophthalmic franchise.[1][6] Licensing value would depend on territorial rights, indication expansion, manufacturing economics, and whether the technology creates a new patent family rather than merely replacing an existing excipient.

What is the revenue exposure and market opportunity?

Verkazia’s commercial value is linked to chronic or recurrent pediatric VKC, a narrower market than dry eye disease but one with meaningful unmet need. The product can generate recurring demand because treatment may extend across allergy seasons and may be restarted in recurrent disease.

Revenue drivers include:

• Number of diagnosed VKC patients
• Pediatric specialist access
• Reimbursement
• Duration of therapy
• Adherence to four-times-daily dosing
• Competition from low-cost compounded or off-label immunomodulators
• Geographic expansion
• Physician preference for steroid-sparing treatment

The principal growth opportunity is indication and platform expansion rather than a broad adult volume market. A reformulated product with less frequent dosing could improve adherence and support premium pricing, especially if supported by pediatric usability and ocular-surface tolerability data.

Key Takeaways

• Verkazia uses a preservative-free cyclosporine 0.1% ophthalmic emulsion.
• Cetalkonium chloride, medium-chain triglycerides, tyloxapol, and poloxamer 188 are central to the formulation’s performance.
• The most valuable excipient opportunities involve validated specialty-grade supply, cationic-emulsion platforms, and improved preservative-free packaging.
• Generic risk is constrained by emulsion equivalence, formulation patents, and manufacturing complexity.
• The strongest follow-on opportunities are lower-frequency dosing, multidose preservative-free delivery, improved tolerability, and indication expansion.
• Orange Book patent listings and litigation outcomes determine the practical U.S. launch timeline.

FAQs About Verkazia Excipients and Commercial Strategy

Can Verkazia be reformulated without cetalkonium chloride?

Yes, technically, but removing cetalkonium chloride may change surface charge, emulsion stability, ocular residence time, tolerability, and patent exposure. The replacement would require a new CMC and equivalence strategy.

Is Verkazia a nanomicellar cyclosporine product?

No. Verkazia is an ophthalmic emulsion. Cequa uses a nanomicellar delivery system, while Vevye is a cyclosporine ophthalmic solution.[1][4][5]

Can a generic Verkazia use different excipients?

Potentially. The applicant must demonstrate equivalence under the applicable FDA pathway and assess formulation patent claims. Different excipients can increase both regulatory and litigation risk.

Why does Verkazia use single-dose containers?

Single-dose packaging supports preservative-free administration and reduces contamination risk during pediatric use. The tradeoff is higher packaging cost and greater product waste.

What is the best commercial white-space opportunity around Verkazia?

A stable, preservative-free multidose product with lower dosing frequency and improved pediatric usability has the clearest commercial white space. Its value would depend on demonstrable adherence, tolerability, and patent differentiation.

References

1. U.S. Food and Drug Administration. (2021). Verkazia (cyclosporine ophthalmic emulsion) 0.1% prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2018). Restasis (cyclosporine ophthalmic emulsion) prescribing information.
4. U.S. Food and Drug Administration. (2018). Cequa (cyclosporine ophthalmic solution) prescribing information.
5. U.S. Food and Drug Administration. (2023). Vevye (cyclosporine ophthalmic solution) prescribing information.
6. European Medicines Agency. (2015). Ikervis: EPAR product information.